Asymmetric antibody with improved cytotoxicity against cancer cells

Patent metadata

Field	Value
Publication number	US-2024383998-A1
Application number	US-202218287505-A
Country	US
Kind code	A1
Filing date	Apr 20, 2022
Priority date	Apr 20, 2021
Publication date	Nov 21, 2024
Grant date	—

Abstract

The present disclosure relates to an anti-CD20 asymmetric antibody including a single-chain variable fragment (scFv) on one side and an antigen-binding fragment (Fab) on the other side. Compared to an antibody having a symmetric structure, the asymmetric antibody of the present disclosure effectively activates complements and exhibits significantly improved complement-dependent cytotoxicity (CDC), and thus can be advantageously used as an effective therapeutic agent or therapeutic adjuvant for treating cancer.

First claim

1 . An anti-CD20 asymmetric antibody with improved complement-dependent cytotoxicity (CDC) or an antigen-binding fragment thereof, comprising:
(a) a single-chain variable fragment (scFv) comprising LCDR1 of SEQ ID NO 16, LCDR2 of SEQ ID NO 18, LCDR3 of SEQ ID NO 20, HCDR1 of SEQ ID NO 24, HCDR2 of SEQ ID NO 26 and HCDR3 of SEQ ID NO 28; and (b) an antigen-binding fragment (Fab) comprising LCDR1 of SEQ ID NO 33, LCDR2 of SEQ ID NO 35, LCDR3 of SEQ ID NO 37, HCDR1 of SEQ ID NO 42, HCDR2 of SEQ ID NO 44 and HCDR3 of SEQ ID NO 46.

2 . The anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , wherein the scFv comprises a light chain variable region (V L ) sequence of SEQ ID NO 51.

3 . The anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , wherein the scFv comprises a heavy chain variable region (V H ) sequence of SEQ ID NO 52.

4 . The anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , wherein the scFv comprises a sequence selected from a group consisting of LFR1 of SEQ ID NO 15, LFR2 of SEQ ID NO 17, LFR3 of SEQ ID NO 19, LFR4 of SEQ ID NO 21, HFR1 of SEQ ID NO 23, HFR2 of SEQ ID NO 25, HFR3 of SEQ ID NO 27 and HFR4 of SEQ ID NO 29.

5 . The anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , wherein the scFv is in the form of V L -linker-V H .

6 . The anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 5 , wherein the linker is a combination of Gly and Ser.

7 . The anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , wherein the Fab comprises a light chain variable region (V L ) sequence of SEQ ID NO 53.

8 . The anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , wherein the Fab comprises a heavy chain variable region (V H ) sequence of SEQ ID NO 54.

9 . The anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , wherein the Fab comprises a sequence selected from a group consisting of LFR1 of SEQ ID NO 32, LFR2 of SEQ ID NO 34, LFR3 of SEQ ID NO 36, LFR4 of SEQ ID NO 38, HFR1 of SEQ ID NO 41, HFR2 of SEQ ID NO 43, HFR3 of SEQ ID NO 45 and HFR4 of SEQ ID NO 47.

10 . The anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , wherein the Fab comprises a C κ (C kappa) sequence of SEQ ID NO 39.

11 . The anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , wherein the Fab comprises a C H 1 sequence of SEQ ID NO 48.

12 . The anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , wherein the Fab is in the form of V L -C κ -linker-V H -C H 1.

13 . The anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 12 , wherein the linker is a combination of Gly and Ser.

14 . A nucleic acid molecule encoding the anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 .

15 . A vector comprising the nucleic acid molecule according to claim 14 .

16 . An isolated host cell transformed with the vector according to claim 15 .

17 . A pharmaceutical composition for preventing or treating cancer, comprising the anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof or a vector including the nucleic acid molecule as an active ingredient.

18 . A method for preventing or treating cancer, comprising a step of administering a pharmaceutically effective amount of the anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof or a vector including the nucleic acid molecule to a subject.

19 . A therapeutic use of the anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof or a vector including the nucleic acid molecule.

20 . A composition for diagnosing cancer, comprising the anti-CD20 asymmetric antibody or an antigen-binding fragment thereof according to claim 1 , a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof or a vector including the nucleic acid molecule as an active ingredient.

21 . A method for preparing an anti-CD20 asymmetric antibody with improved complement-dependent cytotoxicity (CDC) or an antigen-binding fragment thereof, comprising:
(a) a step of preparing a single-chain variable fragment (scFv) comprising LCDR1 of SEQ ID NO 16, LCDR2 of SEQ ID NO 18, LCDR3 of SEQ ID NO 20, HCDR1 of SEQ ID NO 24, HCDR2 of SEQ ID NO 26 and HCDR3 of SEQ ID NO 28; and (b) a step of preparing an antigen-binding fragment (Fab) comprising LCDR1 of SEQ ID NO 33, LCDR2 of SEQ ID NO 35, LCDR3 of SEQ ID NO 37, HCDR1 of SEQ ID NO 42, HCDR2 of SEQ ID NO 44 and HCDR3 of SEQ ID NO 46.

22 . A method for preparing a nucleic acid molecule encoding an anti-CD20 asymmetric antibody with improved complement-dependent cytotoxicity (CDC) or an antigen-binding fragment thereof, comprising:
(a) a step of preparing a nucleic acid molecule encoding a single-chain variable fragment (scFv) comprising LCDR1 of SEQ ID NO 16, LCDR2 of SEQ ID NO 18, LCDR3 of SEQ ID NO 20, HCDR1 of SEQ ID NO 24, HCDR2 of SEQ ID NO 26 and HCDR3 of SEQ ID NO 28; and (b) a step of preparing a nucleic acid molecule encoding an antigen-binding 5 fragment (Fab) comprising LCDR1 of SEQ ID NO 33, LCDR2 of SEQ ID NO 35, LCDR3 of SEQ ID NO 37, HCDR1 of SEQ ID NO 42, HCDR2 of SEQ ID NO 44 and HCDR3 of SEQ ID NO 46.

Assignees

• Univ Korea Res & Bus Found
• Sg Medical Inc

Inventors

• Jung Sang Taek
• Lee Ji Chul
• Min Sung-Won
• Bae Gong Deuk
• Kwon Hyeong Sun
• Lee Sang Min

Classifications

• C07K2317/60

  characterized by non-natural combinations of immunoglobulin fragments · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K16/2887 Primary

  against CD20 · CPC title